Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+1.14%
$87.85
100% positive prob.
5-Day Prediction
+1.95%
$88.55
100% positive prob.
20-Day Prediction
+2.36%
$88.91
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q1 2026 | BUY | +1.14% | +1.95% | +2.36% | 100.0% | +12.88% |
| Q4 2025 | SELL | -1.79% | -3.01% | -6.21% | 100.0% | +2.71% |
SEC 8-K filings with transcript text
May 6, 2026 · 100% conf.
1D
+1.14%
$87.85
Act: +0.58%
5D
+1.95%
$88.55
Act: +12.88%
20D
+2.36%
$88.91
Act: +9.16%
2 cvs_ex99x1q1-26.htm
Document
Exhibit 99.1
•First quarter total revenues increased to $100.4 billion, up 6.2% year-over-year
•First quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57
•Raising full-year 2026 guidance:
◦GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14
◦Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20
◦Cash flow from operations guidance to at least $9.5 billion from at least $9.0 billion
WOONSOCKET, RHODE ISLAND, May 6, 2026 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2026.
“CVS Health continues to provide what people want most from health care: a connected, convenient, cost-effective engagement experience across our unique collection of businesses. We build trust every day in communities across the country by providing better access, affordability and care to nearly 185 million people. Our positive performance is driven by strong execution across our enterprise. We will continue to build momentum through delivering on our strategy and a steadfast focus on our purpose - to simplify health care one person, one family and one community at a time.”
- David Joyner, CVS Health Chairman and CEO
Three Months Ended March 31, Year Ending
December 31,
In billions, except per share amounts 20262025 2026 Projected
Total revenues $100.4 $94.6 At least $405.0
Diluted earnings per share $2.30 $1.41 $6.24-$6.44
Adjusted EPS (2) $2.57 $2.25 $7.30-$7.50
Cash flow from operations $4.2 $4.6 At least $9.5
First quarter GAAP diluted EPS of $2.30 increased from $1.41 in the prior year. Adjusted EPS of $2.57 increased from $2.25 in the prior year, primarily due to improved adjusted operating income in the Health Care Benefits segment, reflecting continued execution on the Health Care Benefits segment margin recovery plan.
The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.
1
Consolidated first quarter results
Three Months Ended March 31,
In millions, except per share amounts20262025Change
Total revenues $100,426 $94,588 $5,838
Operating income 4,680 3,374 1,306
Adjusted operating income (1) 5,150 4,579 571
Net income 2,957 1,782 1,175
Diluted earnings per share $2.30 $1.41 $0.89
Adjusted EPS (2) $2.57 $2.25 $0.32
For the three months ended March 31, 2026 compared to the prior year:
•Total revenues increased 6.2% driven by revenue growth across all operating segments.
•Operating income increased 38.7% primarily due to the increase in adjusted operating income described below, as well as the absence of a $387 million legacy litigation charge and a $247 million pre-tax loss on the wind down and sale of Accountable Care assets, both recorded in the prior year.
•Adjusted operating income increased 12.5% primarily driven by an increase in the Health Care Benefits segment. See pages 3 through 5 for additional discussion of the adjusted operating income performance of the Company’s segments.
Operational Updates
•The release of the U.S. Centers for Medicare & Medicaid Services’ improved Medicare Advantage final rate notice and home health assessment policy enable strong member service and more performance clarity for 2027.
•Aetna® announced significant progress in streamlining the prior authorization reform, exceeding industry commitments across all benchmarks: standardizing data requirements for 88% of prior authorization volume, approving more than 95% of eligible prior authorizations within 24 hours, processing 83% of prior authorizations in real time and eliminating more than 1 million provider calls through automation and digital tools.
•CVS Health announced Health100, a health technology services subsidiary, which will use Google Cloud’s AI technologies to deliver a fully integrated health care engagement platform to provide a connected, proactive and personalized experience for American consumers.
•CVS Pharmacy® continues to increase community access to care, including through the unveiling of small pharmacy-focused locations in 2026.
2
Health Care Benefits segment
The Health Care Benefits segment offers a full range of insured and self-insured (“ASC”) medical, pharmacy, dental and behavioral health products and services. The segment results for the three months ended March 31, 2026 and 2025 were as follows:
Three Months Ended March 31,
In millions, except percentages20262025Change
Total revenues$35,971$34,810$1,161
Adjusted operating income (1) 3,0411,9931,048
Medical benefit ratio (“MBR”) (3) 84.6 %87.3 %(2.7)%
Medical membership (4) 26.027.1(1.1)
Feb 10, 2026 · 100% conf.
1D
-1.79%
$74.34
Act: +1.74%
5D
-3.01%
$73.42
Act: +2.71%
20D
-6.21%
$71.00
cvs-202602100000064803false00000648032026-02-102026-02-10
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 10, 2026
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
One CVS Drive, Woonsocket, Rhode Island 02895 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (401)765-1500
Former name or former address, if changed since last report: N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareCVSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.
On February 10, 2026, CVS Health Corporation issued a press release announcing results for the three months and full year ended December 31, 2025. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
99.1Press Release of CVS Health Corporation dated February 10, 2026 (furnished under Item 2.02).
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:February 10, 2026By:/s/ Brian O. Newman Brian O. Newman Executive Vice President and Chief Financial Officer
Oct 29, 2025
cvs-202510290000064803false00000648032025-10-292025-10-29
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):October 29, 2025
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
One CVS Drive, Woonsocket, Rhode Island 02895 (Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (401) 765-1500
Former name or former address, if changed since last report: N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareCVSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.
On October 29, 2025, CVS Health Corporation issued a press release announcing results for the three months ended September 30, 2025. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
99.1Press Release of CVS Health Corporation dated October 29, 2025 (furnished under Item 2.02)
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:October 29, 2025By:/s/ Brian O. Newman Brian O. Newman Executive Vice President and Chief Financial Officer
This page provides CVS Health Corporation (CVS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CVS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.